Jennifer Kelly Shepphird, PhD | Authors


Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration

January 06, 2015

Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.

Costs of Immunotherapies Continue Debate

December 31, 2014

The FDA approved nivolumab for patients with advanced melanoma in December 2014, joining 6 other melanoma treatments approved in the past 3 years, including monoclonal antibodies pembrolizumab and ipilimumab.